About: Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 16 February 2010

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2010 (fr) наукова стаття, опублікована в березні 2010 (uk) im März 2010 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 16 February 2010 (en) artículu científicu espublizáu en febreru de 2010 (ast) գիտական հոդված հրատարակված 2010 թվականի փետրվարի 16-ին (hy)
publication date	wds:Q60620763-03A88BE5-05EB-4045-B917-DFA07476DD87
publication date	2010-02-16 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q60620763-57EA4984-BCC4-436A-9804-7CA9DB734E7F
language of work or name	English
author name string	wds:Q60620763-41BE8FD8-0CE8-4C34-B25A-96626A8DBBF2 wds:Q60620763-41F9D69E-CED5-4A75-B679-7DB8A47810FC wds:Q60620763-98010E62-5502-40F3-BE6E-1DF1FA857C51 wds:Q60620763-9C764CAB-D432-4C29-A36F-94B1A60F093C wds:Q60620763-9F1D63CA-5B02-4329-AF74-9DF03201564A wds:Q60620763-B443A211-3E63-4B42-9A99-7344C06389EF wds:Q60620763-C0A01078-A707-4B00-9659-9A6A6C44D936 wds:Q60620763-DB9D421B-7D5D-4C67-82D4-9DAF2B313A40
author name string	Benjamin Besse Jean-Charles Soria Xinqun Yang Cheng-Pang Hsu David Khayat Egbert Smit Jeffrey Wiezorek David Reese
rdfs:label	Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer (en) Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer (nl)
skos:prefLabel	Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer (en) Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer (nl)
name	Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer (en) Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer (nl)
author	wds:Q60620763-CDC23E36-D4DA-4EBF-819E-854751DD2C6D
author	Fiona Blackhall
title	wds:Q60620763-F50AA47D-4B0B-4BC6-BD7A-03762F9F4B52
title	Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer (en)
page(s)	wds:Q60620763-C55EE1FD-3FE0-449E-AB24-5B731CE75ADA
page(s)	1527-1533
instance of	wds:Q60620763-DCAE3866-2C94-49C1-A85E-2673B583768C
instance of	scholarly article
main subject	wds:Q60620763-79B516B1-6996-4C5E-BB08-482CBF60E6D3 wds:Q60620763-7A01E44F-5441-4816-926A-1D1C4DD16225 wds:Q60620763-D1B0E7F0-A744-402B-B859-61DD048A674C wds:Q60620763-F48534AE-467F-44FA-AD31-27F674F155CC
main subject	bevacizumab wd:Q423762 carboplatin lung cancer
PubMed ID	wds:Q60620763-691AF3D0-BC24-426F-862D-A92F47CD0355
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/20159815
PubMed ID	20159815
published in	wds:Q60620763-CFDDF59E-CB4C-44A4-A8B0-4BE9D8ABC4D3
published in	Journal of Clinical Oncology
issue	wds:Q60620763-D5299266-0FD0-41B1-8C3A-D8CF58033E62
volume	wds:Q60620763-3E3F45E3-FDA9-4CAF-B1FD-A8144EFA6E27
issue	9
volume	28
DOI	wds:Q60620763-AA3734C5-EB49-4880-BD68-42D26092FD6A
DOI	http://dx.doi.org/10.1200/JCO.2009.25.4847
DOI	10.1200/JCO.2009.25.4847
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q60620763
is cites work of	Getting TRAIL back on track for cancer therapy Onto better TRAILs for cancer treatment Death receptors as targets in cancer Regulating TRAIL receptor-induced cell death at the membrane : a deadly discussion Apoptotic agents Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family Drug resistance in cancer: an overview. TRAIL shows potential cardioprotective activity Targeted ovarian cancer treatment: the TRAILs of resistance. Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics Antitumor Activity of a Mesenchymal Stem Cell Line Stably Secreting a Tumor-Targeted TNF-Related Apoptosis-Inducing Ligand Fusion Protein An optimized antibody-single-chain TRAIL fusion protein for cancer therapy. Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level Targeted therapies for lung cancer: clinical experience and novel agents Pulsed focused ultrasound exposures enhance locally administered gene therapy in a murine solid tumor model Targeting the apoptosis pathway in hematologic malignancies Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy Lung cancer therapeutics that target signaling pathways: an update Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma The therapeutic potential of TRAIL receptor signalling in cancer cells. Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model. Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death. Targeted therapies in non-small cell lung carcinoma: what have we achieved so far? Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL. Pentamerisation of a scFv directed against TRAIL receptor 2 increases its antitumour efficacy Carbenoxolone enhances TRAIL-induced apoptosis through the upregulation of death receptor 5 and inhibition of gap junction intercellular communication in human glioma. Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists Death Receptors: New Opportunities in Cancer Therapy. Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software